Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction
|
|
- Lenard Underwood
- 5 years ago
- Views:
Transcription
1 Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction Masahisa Shimpo, MD, PhD; David A. Morrow, MD, MPH; Ellen O. Weinberg, PhD; Marc S. Sabatine, MD, MPH; Sabina A. Murphy, MPH; Elliott M. Antman, MD; Richard T. Lee, MD Background Mechanically overloaded cardiomyocytes secrete a soluble interleukin-1 receptor family member called ST2. Serum levels of ST2 are associated with prognosis in nonischemic heart failure, but the predictive value of ST2 in patients with acute myocardial infarction is unknown. Methods and Results ST2 levels were measured in serum from 810 patients with acute myocardial infarction in the Thrombolysis In Myocardial Infarction (TIMI) 14 (362 patients) and Enoxaparin and TNK-tPA With or Without GPIIb/IIIa Inhibitor as Reperfusion Strategy in STEMI (ENTIRE)-TIMI 23 (448 patients) clinical trials. Baseline levels of ST2 were significantly higher in those patients who died (0.379 versus ng/ml, P ) or developed new congestive heart failure (0.287 versus ng/ml, P 0.009) by 30 days. In an analysis of outcomes at 30 days by ST2 quartiles, both death (P 0.001) and the combined death/heart failure end point (P 0.001) showed a significant graded association with levels of ST2; furthermore, in-hospital death (P 0.003) and death/heart failure (P 0.004) were also significantly associated with higher ST2 levels. In a logistic regression analysis that controlled for important clinical factors, increasing levels of ST2 remained associated with death at 30 days (P 0.047). ST2 levels rose during the first day after infarction and were maximal at 12 hours; ST2 levels at 12 hours were also independently associated with death at 30 days (P 0.001). Conclusions Serum levels of the interleukin-1 receptor family member ST2 predict mortality and heart failure in patients with acute myocardial infarction. These data suggest that ST2 may be a useful biomarker and that this novel inflammatory receptor may play a role in cardiac pathophysiology. (Circulation. 2004;109: ) Key Words: myocardial infarction prognosis receptors interleukins The ST2 gene (also known as T1, IL1RL1, or Fit1) is a member of the interleukin-1 receptor host defense/inflammation family. 1,2 The protein product of ST2 encodes a transmembrane receptor form (ST2L) and a truncated soluble receptor form (ST2) that can be detected in human serum. 3,4 Although ST2 is an orphan receptor (ligand currently unknown), it is known that ST2 directs Th2 lymphocyte function. 5 Genomic technology was used to identify ST2 as a gene markedly induced in mechanically overloaded cardiac myocytes. 6,7 This suggests that ST2 is induced in conditions of myocardial overload such as myocardial infarction, when the remaining viable myocardium must bear more stress. Indeed, soluble ST2 levels are increased in the serum of patients 1 day after myocardial infarction. 6 Furthermore, ST2 serum levels predict outcome in patients with heart failure, and a change in ST2 over time is also associated with prognosis. 7 These data suggest that measurement of serum levels of ST2 may provide insight into the hemodynamic burden of the myocardium. The relationship between this novel interleukin-1 receptor family member and clinical outcomes in acute myocardial infarction is undefined. Thus, the present study was designed to test the hypothesis that serum ST2 levels are associated with the risk of death or heart failure in patients presenting with ST-elevation myocardial infarction (STEMI). To do this, we measured ST2 levels in serum from patients with STEMI enrolled in the Thrombolysis in Myocardial Infarction (TIMI) 14 and Enoxaparin and TNK-tPA With or Without GPIIb/IIIa Inhibitor as Reperfusion Strategy in STEMI (ENTIRE)-TIMI 23 trials. Methods Study Populations The TIMI 14 trial was a randomized, open-label, dose-ranging study of combination reperfusion therapy for patients with STEMI conducted between March 1997 and July Specifically, this study was an angiographic trial that evaluated several combinations of fibrinolytic with the glycoprotein IIb/IIIa antagonist abciximab. 8,9 Received July 28, 2003; de novo received December 15, 2003; revision received February 9, 2004; accepted February 10, From the Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass. Brigham and Women s Hospital has filed for a patent on ST2, with Dr Lee as inventor. Correspondence to Richard T. Lee, MD, Cardiovascular Division, Brigham and Women s Hospital, 65 Landsdowne St, Cambridge, MA rlee@rics.bwh.harvard.edu 2004 American Heart Association, Inc. Circulation is available at DOI: /01.CIR A 2186
2 Shimpo et al ST2 and Myocardial Infarction 2187 TABLE 1. Baseline Clinical Characteristics According to Quartiles of ST2 Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend P Q4 vs Q1 Range, ng/ml n Time from chest pain to randomization, h Age, y Male, White, Past medical history, Hypertension Congestive heart failure Angina Diabetes Family history of CAD Hypercholesterolemia Current smoker Physical findings Weight, kg Systolic BP, mm Hg Heart rate, bpm Killip class II through IV, Diagnostic testing ctni 0.1 ng/ml,* BNP 80 pg/ml,* CRP 1.5 ng/ml, Creatinine, mg/dl Anterior myocardial infarction, Extent of CAD (50 stenosis), vessel vessel vessel Ejection fraction, Q4 indicates quartile 4; Q1, quartile 1; CAD, coronary artery disease; and BP, blood pressure. *Measured in the ENTIRE-TIMI 23 population only; n 448, except n 469. The ENTIRE-TIMI 23 trial was an open-label, dose-ranging, multicenter study conducted between February 2000 and September 2001 to evaluate enoxaparin as adjunctive antithrombin therapy with various forms of pharmacological reperfusion, including full-dose tenecteplase and half-dose tenecteplase plus abciximab. 10 In both studies, patients were eligible for inclusion if they had a qualifying episode of ischemic discomfort of at least 30 minutes within 6 hours (ENTIRE) or 12 hours (TIMI 14) and exhibited at least 0.1-mV ST-segment elevation in 2 contiguous ECG leads. Exclusion criteria for both trials included increased risk of hemorrhage, severe renal insufficiency, and cardiogenic shock. anti-human ST2 antibody was added into the microwell and incubated. After a second washing, the peroxidase substrate was added, and the optical density at 450 nm was determined. High-sensitivity C-reactive protein (hs-crp, Dade-Behring Inc), creatine kinase-mb isoenzyme (CK-MB), B-type natriuretic peptide (BNP, Shionoria BNP), and cardiac troponin I (ctni; ACS:180, Bayer Diagnostics) were measured by previously described methods Creatine kinase isoenzyme levels were measured locally at the enrolling site on admission, at 3 hours, and at 6- to 8-hour intervals for the first 24 hours. Because of sample availability limitations, BNP levels were measured in samples from ENTIRE-TIMI 23 but not TIMI 14. Laboratory Analyses Serum samples collected at baseline and 1, 3, 12, and 24 hours after enrollment in TIMI 14 were evaluated. Serum samples from the ENTIRE-TIMI 23 trial were collected only at baseline. Serum was isolated within 60 minutes of sample collection and stored at 20 C or colder until shipped to the TIMI Biomarker Core Laboratory (Boston, Mass), where samples were maintained at 70 C. Soluble ST2 was measured by a sandwich double monoclonal antibody ELISA method (Medical & Biological Laboratories Co, Ltd). Serum samples or standards were incubated in microwells coated with anti-human ST2 antibody. After washing, peroxidase-conjugated Statistical Analysis Patients were divided into quartiles on the basis of their serum levels of ST2 at the time of enrollment. ST2 levels are described with the median and 25th and 75th percentiles. The association between baseline clinical characteristics and quartiles of ST2 were analyzed with the Kruskal-Wallis test for continuous variables and the 2 test for categorical variables. Correlations between ST2 and other continuous baseline variables were studied with a nonparametric (Spearman) correlation coefficient. For evaluation of association with clinical outcomes, ST2 was compared between patients who met a study end point and those who did not with the Wilcoxon rank-sum
3 2188 Circulation May 11, 2004 TABLE 2. Correlation Between ST2 and Continuous Variables Variable Spearman s r P Time from chest pain to randomization, h Age, y Weight, kg Heart rate, bpm CK-MB peak ctni* CRP BNP* Creatinine LVEF CAD indicates coronary artery disease; LVEF, left ventricular ejection fraction. *Measured in the ENTIRE-TIMI 23 population only; n 448, except n 469. test. Multivariate analysis of the association of ST2 (continuous variable) with outcomes was performed with logistic regression that included terms for established predictors of mortality in STEMI. 14 Except where stated, results presented are for the combined TIMI 14 and ENTIRE-TIMI 23 study population. Results Baseline ST2 and Clinical Variables Most baseline clinical characteristics, including gender, age, weight, and extent of coronary artery disease, did not correlate with baseline ST2 levels (Table 1). Few patients in this population had either a prior history of or presented with clinical evidence of heart failure. Heart rate (P ) and systolic blood pressure (P 0.05) were associated with ST2 levels, consistent with the theory that ST2 is secreted by cardiac myocytes under biomechanical stress. Patients with the highest levels of ST2 were more likely to have presented with an anterior myocardial infarction (P 0.035) and to present later after chest pain onset (P ). The biomarkers ctni, BNP, and CRP, which have all been shown to predict outcome after myocardial infarction, 13,15,16 were correlated with ST2 by quartile analysis and, with the exception of BNP, showed statistically significant but quantitatively weak correlations when evaluated as continuous variables (Table 2). ST2 and Clinical Outcomes For the combined cohort of 810 patients, baseline ST2 was significantly associated with clinical outcomes at 30 days (Table 3). Specifically, levels of ST2 were significantly higher at presentation among patients who subsequently died (P ) or who developed new or worsening congestive heart failure (P 0.009) by 30 days after enrollment. Dichotomized at the median, elevated baseline levels of ST2 were indicative of higher mortality through 30 days of follow-up (log-rank P ; Figure 1). Moreover, in an analysis by quartiles of ST2, the risk of death (P 0.001) and the composite of death or congestive heart failure (P 0.001) increased in a graded, stepwise fashion with higher levels of ST2 (Table 4). This association between ST2 and clinical TABLE 3. Association Between Baseline ST2 Concentration and Outcomes Outcome (30 Days) n Median (25th, 75th Percentiles), ng/ml P Dead (0.267, 0.611) Alive (0.178, 0.340) Recurrent MI (0.171, 0.259) 0.11 No MI (0.181, 0.348) CHF (0.237, 0.470) No CHF (0.178, 0.345) Death/CHF (0.246, 0.590) No death/chf (0.177, 0.339) MI indicates myocardial infarction; CHF, congestive heart failure. events was homogeneous between the 2 individual trials (TIMI 14 and ENTIRE-TIMI 23, P for heterogeneity 0.8). Evolution of ST2 Serum Levels Baseline ST2 levels analyzed by quartile were significantly correlated with the time to randomization (Tables 1 and 2). This was not surprising, because on the basis of our prior studies, ST2 levels are anticipated to increase on the first day after coronary occlusion and to return to normal over the next 14 days. 6 Among the TIMI 14 patients, analysis of serial measurements of serum ST2 in 228 patients revealed an increase with time, with most patients reaching a peak ST2 level at 12 hours (Figure 2). Multivariate Analysis After controlling for established clinical predictors in STEMI, including age, heart rate, systolic blood pressure, location of myocardial infarction, Killip class, and time from onset of chest pain, increasing levels of ST2 (per 1-ng/mL rise) remained an independent predictor of death at 30 days (OR 1.77, 95 CI 1.01 to 3.12; P 0.047). Data on ST2 and 3 established biomarkers (BNP, hs-crp, and ctni) were available in ENTIRE-TIMI 23. In this data set, mortality through 30 days showed a significant association with quartiles of ctni (quartiles 1 through 4, respectively: 0, 2.7, 2.7, and 7.9; P 0.009) and BNP (quartiles 1 through 4, respec- Figure 1. Probability of death through 30 days after presentation with STEMI by serum ST2 level at baseline (ST2 less than median and ST2 greater than or equal to median).
4 Shimpo et al ST2 and Myocardial Infarction 2189 TABLE 4. Association Between Baseline ST2 Quartiles and Outcomes Outcome Quartile 1, Quartile 2, Quartile 3, Quartile 4, P trend P Q4 vs Q1 In-hospital Death Recurrent MI Death/CHF Day Death MI CHF Death/CHF MI indicates myocardial infarction; CHF, congestive heart failure. tively: 0.6, 1.4, 0.9, and 10.7; P 0.001) but not hs-crp (quartiles 1 through 4: 4.4, 1.8, 1.8, and 5.4; P 0.3). The association between ST2 and mortality was no longer significant when BNP and ctni were added to the clinical model (limited to ENTIRE-TIMI 23). The predictive capacity of ST2 ascertained at later time points (3 and 12 hours in TIMI 14) was also evaluated and revealed a similar association between ST2 at 12 hours and mortality risk (OR 1.27, 95 CI 1.10 to 1.47; P 0.001). In multivariate analysis that included each of the clinical factors (age, heart rate, systolic blood pressure, location of myocardial infarction, Killip class, and time from onset of chest pain) and TIMI flow grade in the infarct-related artery, ST2 remained independently associated with mortality (P 0.01). Discussion In the present study, we explored the potential role of serum measurement of a recently identified receptor of the interleukin-1 family in acute myocardial infarction. The soluble form of this receptor is rapidly secreted by cardiac myocytes when the cells are biomechanically overloaded; this suggests that the receptor may play a role in conditions in which the myocardium is suddenly overloaded, such as in myocardial infarction. To explore this, we measured serum ST2 levels at the time of presentation in a cohort of patients with ST-elevation myocardial infarction. The results demonstrate that levels of ST2 at the time of presentation with STEMI are associated with in-hospital and 30-day mortality. Furthermore, multivariate analysis demonstrated that ST2 level is independently associated with outcome after controlling for established clinical risk indicators in STEMI. The significance of these data is twofold. Foremost, these data suggest that the interleukin-1 receptor family, which participates in host defense and differentiation of T cells, 1 may participate in early events in acute myocardial infarction. These data support further investigation of this receptor as a potential novel target for modifying prognosis in patients with myocardial infarction. Secondarily, ST2 represents a novel biomarker that offers prognostic information in patients with acute myocardial infarction that is independent of clinical predictors. The present report extends our prior work demonstrating an association between ST2 and mortality among patients with nonischemic congestive heart failure, 7 another condition of myocardial overload. The mechanisms of induction and regulation of ST2 expression in acute myocardial infarction are not known. The mechanical overload may induce ST2, but in addition, proinflammatory cytokines from damaged tissues may activate neighboring cells to produce ST2. ST2 has been shown to regulate the expression of proinflammatory cytokines from Figure 2. Evolution of ST2 serum levels over 24 hours after presentation for acute myocardial infarction. Each line represents 1 of 228 patients in TIMI 14 study who had serum samples available at all 5 time points. Peak values occurred at 12 hours in most patients, although some patients with particularly high levels had peak values at 24 hours.
5 2190 Circulation May 11, 2004 macrophage, which may serve to prevent uncontrolled inflammatory reactions. It has also been shown that ST2 released in response to stress or injury can contribute toward the polarization of T helper cells to the Th2 phenotype. Myocardial infarction is associated with humoral (eg, cytokines and reactive oxygen species) and cell-mediated (eg, neutrophils and mononuclear cells) inflammatory reactions, which are a prerequisite for healing and scar formation. ST2 may contribute to this process, which can affect prognosis. Although not excluded by the present study, it is unlikely that the relationship of ST2 and outcome after myocardial infarction is simply a reflection of the association of chronic elevations in inflammatory markers such as CRP and risk of myocardial infarction. ST2, like BNP, may be synthesized by cardiac myocytes themselves, and data from patients without apparent ischemic disease suggest that ST2 predicts prognosis in the absence of coronary artery disease. Furthermore, preliminary data suggest that ST2 levels in outpatients with stable coronary artery disease are unrelated to CRP levels (unpublished observations). Moreover, ST2 showed only a very modest (r 0.10) correlation with hs-crp in the present data set. Although the present data support the complementary value of ST2 for risk assessment when added to a robust clinical model, ST2 did not contribute additional information to BNP and ctni in the smaller data set limited to ENTIRE- TIMI 23. Notably, levels of ST2 were only weakly correlated with a measure of myonecrosis (ctni) and were not associated with the plasma concentration of BNP, which suggests that ST2 reflects pathophysiology distinct from these established biomarkers. Additional studies are necessary to evaluate carefully the prognostic value of ST2 in conjunction with other available biomarkers. The study end points of TIMI 14 and ENTIRE-TIMI 23 were predetermined to be 30 days after enrollment, and thus longer-term follow-up was not available. Although ST2 may be secreted by mechanically overloaded cardiac myocytes, many cells can secrete ST2. Thus, elevations in serum ST2 are not specific for acute myocardial infarction. In addition to nonischemic heart failure, 7 patients with asthma 17 or autoimmune diseases such as systemic lupus erythematosus 18 may also have increased serum ST2 levels. Thus, ST2 measurement is unlikely to be useful in the initial diagnosis of myocardial infarction. However, ST2 levels correlate inversely with ejection fraction in patients with nonischemic heart failure, 7 and additional studies with serial evaluations of ventricular function are necessary to determine whether the source of ST2 in patients with myocardial infarction is the overloaded myocardium. These data lend validity to the concept that genomic technology can reveal a new potential pathophysiological pathway in a common disease. ST2 was identified initially through studies of the interleukin-1 family, but its role in myocardial disease was only recently suggested by genomic studies with DNA microarrays. Studies with DNA microarrays allow identification of potential new disease pathways, but this is only an initial step in understanding the role of the pathway. The association between ST2 and outcome in the present study now provides important data that support a role for ST2 in acute myocardial infarction. However, additional studies of the function of ST2 in myocardial infarction are needed. Furthermore, the ligand for the soluble and membrane ST2 receptors remains unidentified, and understanding the potentially competing roles of the membrane and soluble receptors will require identification of the ligand. Acknowledgments This study was supported in part by grants from the National Heart, Lung, and Blood Institute. Dr Shimpo was supported in part by Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad, the Cell Science Research Foundation, and the Mochida Memorial Foundation for Medical and Pharmaceutical Research. References 1. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol. 2002;14: O Neill L. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem Soc Trans. 2000;28: Tominaga S. A putative protein of a growth specific cdna from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258: Townsend MJ, Fallon PG, Matthews DJ, et al. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191: Walzl G, Matthews S, Kendall S, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med. 2001;193: Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106: Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107: Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial: the TIMI 14 Investigators. Circulation. 1999;99: Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14: the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 2000;21: Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 2002;105: Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy: Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998;31: Morrow DA, Rifai N, Tanasijevic MJ, et al. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem. 2000;46: Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90: Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous npa for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102: de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345: Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335: Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164: Kuroiwa K, Arai T, Okazaki H, et al. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284:
Coronary Heart Disease
Coronary Heart Disease Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction Marc S. Sabatine,
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationDifferential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction
Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationJournal of the American College of Cardiology Vol. 41, No. 8, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 8, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(03)00168-2
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationTo estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome
Original Research Article To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome Mohamed Yasar Arafath 1, K. Babu Raj 2* 1 First Year Post Graduate, 2
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationBiomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in cardiovascular disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationEffect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals
1 Effect of Short-term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Jan Krupicka, MD, Tomas Janota, MD, Zdislava Kasalova, MD, Jaromir Hradec, MD 3rd Department of Internal Medicine, 1st
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationPlasma levels of cardiac troponin (ctn) provide important
Elevated Troponin I Level on Admission Is Associated With Adverse Outcome of Primary Angioplasty in Acute Myocardial Infarction Shlomo Matetzky, MD; Tali Sharir, MD; Michelle Domingo, BS; Marko Noc, MD;
More informationThe impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes
Atherosclerosis 194 (2007) 397 402 The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes Michael N. Zairis,
More informationCombination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction. A TIMI 14 Substudy
Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction A TIMI 14 Substudy C. Michael Gibson, MS, MD; James A. de Lemos, MD; Sabina A. Murphy, MH; Susan
More informationAcute Coronary Syndrome
Acute Coronary Syndrome Clinical Manifestation of CAD Silent Ischemia/asymptomatic Stable Angina Acute Coronary Syndrome (Non- STEMI/UA and STEMI) Arrhythmias Heart Failure Sudden Death Pain patterns with
More informationST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction
European Heart Journal (2003) 24, 1515 1522 ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction Paul W. Armstrong a *, Galen
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationElevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion. A TACTICS-TIMI 18 Substudy
Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion A TACTICS-TIMI 18 Substudy Graham C. Wong, MD; David A. Morrow, MD, MPH; Sabina Murphy, MPH; Nicole Kraimer, MS; Rupal
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationJournal of the American College of Cardiology Vol. 40, No. 10, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 10, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02484-1
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationCorporate Medical Policy
Corporate Medical Policy ST2 Assay for Chronic Heart Failure File Name: Origination: Last CAP Review: Next CAP Review: Last Review: st_assay_for_chronic_heart_failure 2/2015 4/2018 4/2019 4/2018 Description
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationEssam Mahfouz, MD. Professor of Cardiology, Mansoura University
By Essam Mahfouz, MD. Professor of Cardiology, Mansoura University Agenda Definitions Classifications Epidemiology Risk stratification What is new? What is MI? Myocardial infarction is the death of part
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationAcute Coronary Syndrome in Phrae Hospital
Acute Coronary Syndrome in Phrae Hospital Cardiovascular Unit, Department of Medicine, Phrae hospital, Phrae Thailand. Objective: To study the epidemiology, management and outcome of patients with acute
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationWHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.
WHI Form - Report of Cardiovascular Outcome Ver. 6. COMMENTS To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: OMB# 095-044 Exp: 4/06 -Affix label here- Clinical Center/ID:
More informationACS and Heart Failure
ACS and Heart Failure Jonathon Firnhaber, MD, FAAFP Associate Professor The Brody School of Medicine at East Carolina University Greenville, North Carolina Learning Objectives Establish the diagnosis and
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationHeart Online First, published on October 26, 2005 as /hrt
Heart Online First, published on October 26, 2005 as 10.1136/hrt.2005.072975 1 Admission NT-proBNP and it s interaction with admission Troponin T and ST-segment resolution for early risk stratification
More informationEarly diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong
Hong Kong Journal of Emergency Medicine Early diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong CH Ho, W Cheng, G Chu, HF Ho Introduction: Cardiac
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationPreprocedural TIMI Flow and Mortality in Patients With Acute Myocardial Infarction Treated by Primary Angioplasty
Journal of the American College of Cardiology Vol. 43, No. 8, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.11.042
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationEarly Prognostic Usefulness of C-Reactive Protein Added to the Thrombolysis In Myocardial Infarction Risk Score in Acute Coronary Syndromes
Early Prognostic Usefulness of C-Reactive Protein Added to the Thrombolysis In Myocardial Infarction Risk Score in Acute Coronary Syndromes Stefanos G. Foussas, MD a, Michael N. Zairis, MD a, *, Anastassios
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationBIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.
BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS As. MARUSHCHAK M.I. Heart attack symptoms Acute MI Measurement of cardiac enzyme levels Measure cardiac enzyme levels at regular
More informationThe restoration of coronary flow after an
Pharmacological Reperfusion in Acute Myicardial Infarction after ASSENT 3 and GUSTO V [81] DANIEL FERREIRA, MD, FESC Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal Rev Port Cardiol
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationAcute Changes in Circulating Natriuretic Peptide Levels in Relation to Myocardial Ischemia
Journal of the American College of Cardiology Vol. 44, No. 10, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.07.057
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationSupplemental Material
Supplemental Material Supplemental Results The baseline patient characteristics for all subgroups analyzed are shown in Table S1. Tables S2-S6 demonstrate the association between ECG metrics and cardiovascular
More informationΟΙ ΒΙΟΔΕΙΚΤΕΣ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ. Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος ΤΟΥΣΟΥΛΗΣ ΟΙ ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationAtrial natriuretic peptide (ANP) and brain natriuretic
Exertional Changes in Circulating Cardiac Natriuretic Peptides in Patients with Suggested Coronary Artery Disease Sébastien Bergeron, MD, Jacob E. Møller, MD, PhD, Kent R. Bailey, PhD, Horng H. Chen, MD,
More informationA Comparative Evaluation of C-Reactive Protein as a Short-Term Prognostic Marker in Severe Unstable Angina A Preliminary Study
Original Article A Comparative Evaluation of C-Reactive Protein as a Short-Term Prognostic Marker in Severe Unstable Angina A Preliminary Study S Bhagat*, M Gaiha*, VK Sharma**, S Anuradha* Abstract Objective
More informationImproving the Outcomes of
Improving the Outcomes of STEMI Shelley Valaire, ACP; and Robert Welsh, MD, FRCPC Presented at the University of Alberta s 6th Annual Cardiology Update for General Practitioners and Internists, Edmonton,
More informationRISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain
RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain Potential Conflicts of Interest Financial conflicts of
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationMyocardial Infarction
Myocardial Infarction MI = heart attack Defined as necrosis of heart muscle resulting from ischemia. A very significant cause of death worldwide. of these deaths, 33% -50% die before they can reach the
More informationCharacteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure
Journal of the American College of Cardiology Vol. 52, No. 18, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.07.042
More informationMode of admission and its effect on quality indicators in Belgian STEMI patients
2015 Mode of admission and its effect on quality indicators in Belgian STEMI patients Prof dr M Claeys National Coordinator STEMI registry 29-6-2015 Background The current guidelines for the management
More informationAustralian Journal of Basic and Applied Sciences, 9(36) December 2015, Pages: ISSN: Journal home page:
ISSN:1991-8178 Australian Journal of Basic and Applied Sciences Journal home page: www.ajbasweb.com Role of Biochemical Tests Artery Disease (ANP, BNP) in the Evaluation of Patients with Coronary 1 Saad
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationLong-Term Prognostic Value of ST-Segment Resolution in Patients Treated With Fibrinolysis or Primary Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 54, No. 19, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.084
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationThe Thrombolysis In Myocardial Infarction Risk Score in Unstable Angina/ Non ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)03019-x
More informationA case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationThe Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial
Journal of the American College of Cardiology Vol. 49, No. 23, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.12.049
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationObjectives. Identify early signs and symptoms of Acute Coronary Syndrome Initiate proper protocol for ACS patient 10/2013 2
10/2013 1 Objectives Identify early signs and symptoms of Acute Coronary Syndrome Initiate proper protocol for ACS patient 10/2013 2 Purpose of this Education Module: Chest Pain Center Accreditation involves
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationDISCUSSION QUESTION - 1
CASE PRESENTATION 87 year old male No past history of diabetes, HTN, dyslipidemia or smoking Very active Medications: omeprazole for heart burn Admitted because of increasing retrosternal chest pressure
More informationInfluence of Location and Size of Myocardial Infarction on Post-infarction Remodelling
Influence of Location and Size of Myocardial Infarction on Post-infarction Remodelling Masci PG, MD ; Ganame J, MD ; Francone M, MD, PhD # ; Desmet W, MD ; Iacucci I, MD # ; Barison A, MD ; Carbone I,
More informationJournal of the American College of Cardiology Vol. 41, No. 3, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02824-3
More information